<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159796</url>
  </required_header>
  <id_info>
    <org_study_id>P07009</org_study_id>
    <secondary_id>A7501005</secondary_id>
    <nct_id>NCT00159796</nct_id>
  </id_info>
  <brief_title>3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)</brief_title>
  <official_title>A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501005 (Secondary Title: ARES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder is characterized by mood swings that range from high (manic) to low
      (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed
      episodes). Asenapine is an investigational medication for the treatment of manic or mixed
      episodes of bipolar disorder. This is a 3-week study that will test the safety and efficacy
      of this medication. Participants will receive either asenapine, olanzapine (a medication that
      is already approved for the treatment of bipolar mania), or placebo (no active medication).
      Participants will be required to stay in the hospital for at least the first seven days of
      treatment. Participants who complete the 3 week study may be eligible to continue in
      extension studies for an additional 9 (study A7501006) to 49 (study A7501007) weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2004</start_date>
  <completion_date type="Actual">April 28, 2006</completion_date>
  <primary_completion_date type="Actual">March 28, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Day 21 on the Young Mania Rating Scale (YMRS) Total Score</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in the Clinical Global Impression Scale for use in Bipolar Disorder (CGI-BP) Severity of Mania</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in the Positive and Negative Symptom Scale (PANSS) Total Score</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readiness for Discharge Questionnaire (RDQ)</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in Central Nervous System (CNS) Vital Signs</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in Short Form-36 (SF-36) - Physical Component Summary Scores</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in the Severity of Extrapyramidal Symptoms (EPS)</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Medication Usage</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after last dose (Up to approximately 51 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Each Time Point in YMRS Total Score</measure>
    <time_frame>Days 2, 4, 7, 14, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in the CGI-BP Severity of Depression</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in the CGI-BP Severity of Overall Bipolar Illness</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in SF-36 - Mental Component Summary Scores</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medicine (TSQM) Overall Impact Domain Score at Day 21</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline for Vital Signs</measure>
    <time_frame>Baseline up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 21 in Body Weight</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Post-Baseline Markedly Abnormal Biochemistry Laboratory Changes/Values</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Post-Baseline Markedly Abnormal Endocrinology/Miscellaneous Laboratory Changes/Values</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Post-Baseline Markedly Abnormal Metabolic Chemistry Laboratory Changes/Values</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Post-Baseline Markedly Abnormal Hematology Laboratory Values</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Plasma asenapine concentrations</measure>
    <time_frame>Day 1 (pre-dose), 7, 14 and 21 (or endpoint)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">489</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>Asenapine, 3 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Org 5222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine, 3 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, 3 weeks</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
             diagnosis of bipolar I disorder, current episode manic or mixed.

        Exclusion Criteria:

          -  Participants with unstable medical conditions or clinically significant laboratory
             abnormalities or participants who are rapid cyclers (i.e., have had 4 or more
             (including current) mood episodes in the past 12 months); have any other psychiatric
             disorder other than bipolar I disorder as a primary diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

